Find Nilvadipine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 75530-68-6, Escor, Nivadil, Nivadipine, Fr-34235, Fk 235
Molecular Formula
C19H19N3O6
Molecular Weight
385.4  g/mol
InChI Key
FAIIFDPAEUKBEP-UHFFFAOYSA-N
FDA UNII
0214FUT37J

Nilvadipine
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
1 2D Structure

Nilvadipine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
2.1.2 InChI
InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
2.1.3 InChI Key
FAIIFDPAEUKBEP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
2.2 Other Identifiers
2.2.1 UNII
0214FUT37J
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5-isopropyl-3-methyl-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinecarboxylate

2. Escor

3. Fr 34235

4. Fr-34235

5. Nivadil

2.3.2 Depositor-Supplied Synonyms

1. 75530-68-6

2. Escor

3. Nivadil

4. Nivadipine

5. Fr-34235

6. Fk 235

7. Nivadip

8. Dl-nilvadipine

9. Fr 34235

10. Sk&f 102,362

11. Cl 287,389

12. Fk-235

13. Cl-287389

14. Nilvadipine (arc029)

15. Sk&f-102362

16. 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

17. 3-o-methyl 5-o-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

18. Cl-287,389

19. 0214fut37j

20. 5-isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

21. Skf-102362

22. 3,5-pyridinedicarboxylic Acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) Ester

23. Fr34235

24. Ncgc00167435-01

25. Sk&f-102,362

26. Nilvadipinum [latin]

27. Nilvadipino [spanish]

28. Nivaldipine

29. Nilvadipino

30. Nilvadipinum

31. 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-methyl 5-(1-methylethyl) Ester

32. Nilvadipine [usan:inn:jan]

33. Arc029

34. Brn 3572609

35. Unii-0214fut37j

36. Nivadil (tn)

37. Mfcd00867065

38. Nilvadipine [mi]

39. Nilvadipine [inn]

40. Nilvadipine [jan]

41. Nilvadipine [usan]

42. Dsstox_cid_26624

43. Dsstox_rid_81774

44. Nilvadipine [mart.]

45. Dsstox_gsid_46624

46. Schembl33729

47. (+/-)-nilvadipine

48. Nilvadipine [who-dd]

49. Chembl517427

50. Dtxsid2046624

51. Chebi:31911

52. Faiifdpaeukbep-uhfffaoysa-

53. Gtpl10160

54. Nilvadipine (jp17/usan/inn)

55. Fk235

56. Hms3651j11

57. Hms3714a17

58. Hms3884f16

59. Bcp06007

60. Arc029;fr34235

61. Tox21_112439

62. Bdbm50103634

63. Akos015907577

64. Ccg-220648

65. Db06712

66. Ks-1303

67. Ncgc00167435-02

68. Ncgc00167435-03

69. Ncgc00167435-07

70. 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 5-isopropyl 3-methyl Ester

71. 3,5-pyridinedicarboxylic Acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl-5-(1-methylethyl) Ester

72. 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

73. 5-isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate

74. Ac-28326

75. Hy-14284

76. O3-methyl O5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

77. Cas-75530-68-6

78. Db-055963

79. Ft-0630839

80. N0899

81. S2721

82. Sw219572-1

83. D01908

84. Ab01566895_01

85. 530n686

86. A838445

87. Sr-01000872715

88. Q7037489

89. Sr-01000872715-1

90. O3-methyl O5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-

91. (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

92. 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic Acid O3-methyl Ester O5-propan-2-yl Ester

93. 5-isopropyl 3-methyl (+)-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

94. 5-isopropyl 3-methyl (-)-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

95. 5-isopropyl3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 385.4 g/mol
Molecular Formula C19H19N3O6
XLogP32.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count6
Exact Mass385.12738533 g/mol
Monoisotopic Mass385.12738533 g/mol
Topological Polar Surface Area134 Ų
Heavy Atom Count28
Formal Charge0
Complexity783
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

For the management of vasospastic angina, chronic stable angina and hypertension.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Nilvadipine is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. Nilvadipine is used to treat Prinzmetal's angina, hypertension, and other vascular disorders such as Raynaud's phenomenon. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.


5.2 MeSH Pharmacological Classification

Calcium Channel Blockers

A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)


Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)


5.3 ATC Code

C - Cardiovascular system

C08 - Calcium channel blockers

C08C - Selective calcium channel blockers with mainly vascular effects

C08CA - Dihydropyridine derivatives

C08CA10 - Nilvadipine


5.4 Mechanism of Action

Nilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty